[The treatment of depressive states with opipramol (Insidon--Geigy)].
The authors analyse the findings of a clinical simple-blind trial of the drug Insidon--Geigy in depressive states. This drug was administered in monotherapy for 28 days in average doses of 150 mg daily in a series of 20 inpatients of both sexes and aged 20-60 years, diagnosed with neurotic depressive state. The efficiency of the treatment and its tolerance were estimated on a special Ciba-Geigy Pharma International investigation card through clinical observation, scoring of clinical items, psychological check-up and Hamilton's scale for depression at 0-7-14-21 and 28 days, paraclinical investigations, computer processing (TIM-S) on the basis of a program (in BETA BASIC language in 3.1 version) necessary for determining the polynomial functions for the significant items of the psychopathological syndrome (anxiety, depression, insomnia). The corroboration of the data of clinical and paraclinical observations with the psychologic examination and the computer-processed data reveals the clinical efficacy of Insidon--Geigy in neurotic depression, its good tolerance and low incidence of side effects.
Pirozynski
T
T
Chiriţă
V
V
Saramet
M
M
Boişteanu
P
P
Hrimiuc
V
V
Gottlieb
H
H
Cosmovici
N
N
Luchian
M
M
D000328:Adult; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009888:Opipramol / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011599:Psychopathology; D013997:Time Factors
D009888:Opipramol
Observaţii privind tratamentul stărilor depresive cu opipramol (Insidon--Geigy).